Study of INCA32459 a LAG-3 and PD-1 Bispecific Antibody in Participants With Select Advanced Malignancies

计划入组 120 人 · 首次发布于 2022 年 10 月 13 日

Intrathecal PD-1/VEGF Bispecific Antibody Plus Pemetrexed for Leptomeningeal Metastasis

计划入组 34 人 · 首次发布于 2025 年 2 月 5 日

A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer

计划入组 10 人 · 首次发布于 2019 年 5 月 3 日

FS-118

Dual PD-L1 Checkpoint Inhibitor/CD28 Costimulator (Xencor)

PD-L1 x ABCG2

Cambridge Antibody Technology

New Zealand

PD-RX Pharmaceuticals, Inc.

United States

Latticon Antibody Therapeutics, Inc

United States

China's Biopharma Sector Showcases Innovation Leadership at BIOSeedin 2025 Conference

Akeso's Bispecific Antibodies Show Promise in Lung and Colorectal Cancers

Instil Bio and ImmuneOnco Advance PD-(L)1xVEGF Bispecific Antibody Clinical Development Strategy